Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
- Conditions
- Follicular Lymphoma Grade III (FL III°)Mantle Cell Lymphoma (MCL), Blastoid VariantAggressive Marginal Zone Lymphoma (MZL)Diffuse Large B-cell Lymphoma (DLBCL)Burkitt Lymphoma (BL)
- Interventions
- Procedure: peripheral stem cell collection
- Registration Number
- NCT02983097
- Lead Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
- Brief Summary
The goal of this study is to evaluate efficacy and safety of the combination of lenalidomide, an immunomodulatory drug (IMiD) with a standard immunochemotherapy treatment, called R-DHAP. R-DHAP consists of a monoclonal antibody called Rituximab and chemotherapy consisting of Dexamethasone, high dose Cytarabine, often called Ara-C, and platinum based chemotherapy, either cisplatinum, or, if treatment with cisplatinum is contraindicated, carboplatinum.
- Detailed Description
This is a phase 1/2 study to evaluate the efficacy and safety of lenalidomide added to a standard chemotherapy regime of R-DHAP (Rituximab, Dexamethasone, high-dose Cytarabine, Cis/Carboplatinum) in the treatment of relapsed or refractory high-grade B-cell non-hodgkin-lymphoma (NHL).
The study hypothesis is that the combination of lenalidomide with standard immunochemotherapy will lead to an overall response rate of at least 60%. In this study, 3 rounds of immunochemotherapy in combination with lenalidomide will be administered. After the first or second round of therapy, peripheral hematopoetic stem cells will be harvested. Consolidation treatment with autologous or allogenic peripheral blood stem cell transplantation is recommended in all patients suitable, but is not part of the study.
In phase 1, up to six cohorts of at least 6 patients each will be treated with the study therapy, with lenalidomide in increasing dosages, to determine the maximum tolerated dose (MTD).
In phase 2, 50 patients will be treated with the MTD. Efficacy and safety will be evaluated.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 34
Age: 18-70
Risk groups: All risk groups
histology: diagnosis or a recurrent or primary progressive aggressive b-cell non-hodgkin lymphoma, in particular
- follicular lymphoma grade III
- diffuse large b-cell lymphoma
- burkitt lymphoma
- mantle cell lymphoma, blastoid variant
- aggressive marginal zone lymphoma
Performance status: ECOG 0-2
Criteria for women of childbearing potential:
Women of childbearing potential have to:
- understand the teratogenic risk associated with the study therapy, especially lenalidomide
- understand the need of reliable, uninterrupted birth control from 4 weeks prior to the start of the study drug, during the duration of the study treatment, and 4 weeks after completion of study treatment, and be able to reliably use birth control, except if the patient commits to absolute sexual abstinence, confirmed on a monthly basis
The following are effective methods of contraception:
- implant
- levonorgestrel-releasing intrauterine system (IUS)
- medroxyprogesterone acetate depot
- tubal sterilisation
- sexual intercourse with a vasectomised male partner only, vasectomy must be confirmed by two negative semen analyses
- ovulation-inhibitory progesterone-only pills If not established on effective contraception, the female subject must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated.
- Understand that even if she has amenorrhea, she must follow all the advice on effective contraception
- Understand the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy.
- Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25 mIU/ml on the day of the study visit or in the 3 days prior to the study visit once the subject has been on effective contraception for at least 4 weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence. The test should ensure the subject is not pregnant when she starts treatment.
- Agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks after the end of study treatment, except in the case of confirmed tubal sterilization. These pregnancy tests should be performed on the day of the study visit or in the 3 days prior to the study visit. This requirement also applies to women of childbearing potential who practice complete and continued abstinence.
Male patients have to:
- Agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study therapy if their partner is of childbearing potential and has no contraception.
- Agree not to donate semen during study drug therapy and for one week after end of study drug therapy.
All patients have to:
- Agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy.
- Agree not to share study medication with another person and to return all unused study drug to the investigator
Patients must be able to take low molecular weight heparin as prophylactic anticoagulation
Written informed consent is necessary
- pregnant or lactating females
- already initiated salvage lymphoma therapy (except prephase as specified in this study)
- serious accompanying disorder or impaired organ function causing significant clinical problems and reduced lyfe expectancy, in particular: heart: angina pectoris CCS>2 cardiac failure NYHA>2 and/or EF<45% lungs: FeV1<60%, diffusion capacity <50% of the reference values kidneys: creatinine>2 times the upper reference limit liver: bilirubin >2 times the upper reference limit
- platelets <80000/mm³, leukocytes <2500/³
- CNS involvement of lymphoma
- known hypersensitivity to the medications to be used
- known HIV-positivity
- suspicion that patient compliance will be poor, especially that rules for effective contraception will not be followed
- simultaneous participation in other treatment studies
- non-conformity to eligibility criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description R²-DHAP peripheral stem cell collection Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide Dosage: Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c. peripheral stem cell collection after cycle 1 or 2 R²-DHAP Rituximab Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide Dosage: Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c. peripheral stem cell collection after cycle 1 or 2 R²-DHAP Cisplatin Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide Dosage: Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c. peripheral stem cell collection after cycle 1 or 2 R²-DHAP Carboplatin Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide Dosage: Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c. peripheral stem cell collection after cycle 1 or 2 R²-DHAP Dexamethasone Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide Dosage: Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c. peripheral stem cell collection after cycle 1 or 2 R²-DHAP Cytarabine Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide Dosage: Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c. peripheral stem cell collection after cycle 1 or 2 R²-DHAP PegFilgrastim Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide Dosage: Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c. peripheral stem cell collection after cycle 1 or 2 R²-DHAP Lenalidomide Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide Dosage: Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c. peripheral stem cell collection after cycle 1 or 2
- Primary Outcome Measures
Name Time Method Maximum tolerated dose (MTD) 78 - 85 days The maximum dose of lenalidomide tolerated with acceptable toxicity during phase 1 of this study. The MTD established in phase 1 of this study will be administered to 50 patients in phase 2 of this study.
Overall Response Rate (ORR) 78 - 85 days + 2 years Follow Up The percentage of patients which showed either a partial remission (PR), a complete remission with remaining uncertainty (CRu) or a complete remission (CR) after study treatment.
- Secondary Outcome Measures
Name Time Method tumour control 78 - 85 days + 2 years Follow Up laboratory, BM biopsy
incidence of non-hematological toxicities > grade 2 CTC 78 - 85 days + 2 years Follow Up Progression free survival 78 - 85 days + 2 years Follow Up laboratory, BM biopsy, imaging
feasibility of stem cell mobilization 78 - 85 days + 2 years Follow Up The collection of peripheral stem cells is needed to be able to offer the patient high dose chemotherapy followed by autologous stem cell transplantation after the study treatment has ended.
Stem cell collection of \<2.0 \*10e6 CD34+cells/kg will be considered insufficient.Rate of complete remission 78 - 85 days + 2 years Follow Up laboratory, BM biopsy, imaging
Rate of primary progression 78 - 85 days + 2 years Follow Up The rate of patients which show progressive disease (PD) during or directly after study therapy
Rate of treatment related deaths 78 - 85 days + 2 years Follow Up check survival
Relapse Rate 78 - 85 days + 2 years Follow Up laboratory, BM biopsy, imaging
Overall Survival 78 - 85 days + 2 years Follow Up check survival
incidence and duration of neutropenia and thrombopenia grade 4 78 - 85 days + 2 years Follow Up laboratory WBC \< 1.0 /nl or Plt \< 25 /nl
Trial Locations
- Locations (12)
LMU Klinikum München-Großhadern
🇩🇪München, Germany
Diakonie Krankenhaus Bremen
🇩🇪Bremen, Germany
Universitätsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Universitätsklinikum Essen
🇩🇪Essen, Germany
Universitätsklinikum des Saarlandes
🇩🇪Homburg, Germany
Asklepios Klinik Altona
🇩🇪Hamburg, Germany
Asklepios Klinik St. Georg
🇩🇪Hamburg, Germany
Klinikum Frankfurt/Oder
🇩🇪Frankfurt/Oder, Germany
Westpfalz Klinikum
🇩🇪Kaiserslautern, Germany
Städtisches Klinikum Karlsruhe
🇩🇪Karlsruhe, Germany
Universitätsklinikum Göttingen
🇩🇪Göttingen, Germany
Klinikum Chemnitz
🇩🇪Chemnitz, Germany